Value of Prehospital Troponin Assessment in Suspected Non-ST-Elevation Acute Coronary Syndrome

• Published in: The American journal of cardiology Vol. 122; no. 10; pp. 1610 - 1616
• Main Authors: van Dongen, Dominique N., Fokkert, Marion J., Tolsma, Rudolf T., Badings, Erik A., van der Sluis, Aize, Slingerland, Robbert J., van ‘t Hof, Arnoud W.J., Ottervanger, Jan Paul
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 15.11.2018; Elsevier Limited
• Subjects: Acute Coronary Syndrome - blood; Acute Coronary Syndrome - diagnosis; Acute Coronary Syndrome - epidemiology; Acute coronary syndromes; Age; Angina pectoris; Biomarkers - blood; Body mass index; Calcium-binding protein; Coronary vessels; Diabetes; Electrocardiography; Emergency medical care; Emergency Medical Services; Family medical history; Follow-Up Studies; Heart; Heart attacks; Heart surgery; Hospitals; Humans; Hypertension; Incidence; Ischemia; Netherlands - epidemiology; Paramedics; Patients; Predictive Value of Tests; Prospective Studies; Risk assessment; Risk Assessment - methods; Risk Factors; Risk groups; Stroke; Survival Rate - trends; Troponin; Troponin - blood; Troponin T; Netherlands
• DOI: 10.1016/j.amjcard.2018.07.037
• ISSN: 0002-9149

There is an increasing awareness that prehospital risk stratification in patients with suspected non-ST-elevation acute coronary syndrome (NSTE-ACS) is important. The HEART score accurately identifies patients at low risk and is nowadays fully assessable outside the hospital after the development of point-of-care (POC) troponin tests. However, the added value of the troponin component to the prehospital HEART score has not yet been assessed. This is a prospective cohort study including 700 patients with suspected NSTE-ACS in which prehospital risk stratification using the HEART score was performed by paramedics. Low risk was defined as HEAR or HEART score ≦3. Troponin was measured by a POC troponin T Test device (Roche Cobas h232). Troponin <40 ng/l scored 0 point, troponin ≥40 ng/l scored 2 points. Primary end point was major adverse cardiac events (MACE) within 45 days after inclusion. Mean HEAR score was 4.5 ± 1.6, mean HEART score was 4.7 ± 1.7. Using the HEAR score, a total of 183 patients (26%) were stratified as low risk, whereas using the HEART score, 172 patients (25%) were stratified as low risk (p = 0.001). In both low-risk groups, there were no deaths within 45 days. Using HEAR, MACE occurred in 13 patients (7%) in the low-risk group, whereas using HEART, MACE occurred in 5 patients in the low-risk group (3%, p <0.001). The use of HEART (Area under the curve 0.74) obtained a higher predictive value compared to HEAR (Area under the curve 0.65, p <0.001) for MACE. In conclusion, in patients with suspected NSTE-ACS, the prehospital troponin component of the HEART score has important added predictive value.